MGUS
MCID: MNC006
MIFTS: 48

Monoclonal Gammopathy of Uncertain Significance (MGUS)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Monoclonal Gammopathy of Uncertain Significance

MalaCards integrated aliases for Monoclonal Gammopathy of Uncertain Significance:

Name: Monoclonal Gammopathy of Uncertain Significance 12 15
Monoclonal Gammopathy of Undetermined Significance 12 74 52 71 32
Mgus 12 52

Classifications:



External Ids:

Disease Ontology 12 DOID:7442
ICD10 32 D47.2
UMLS 71 C0026470

Summaries for Monoclonal Gammopathy of Uncertain Significance

NIH Rare Diseases : 52 Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma , macroglobulinemia , or B-cell lymphoma ). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors . People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop. Those with stable levels of monoclonal protein typically do not require treatment.

MalaCards based summary : Monoclonal Gammopathy of Uncertain Significance, also known as monoclonal gammopathy of undetermined significance, is related to waldenstroem's macroglobulinemia and idiopathic neutropenia. An important gene associated with Monoclonal Gammopathy of Uncertain Significance is SDC1 (Syndecan 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Liraglutide and Glucagon have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A blood protein disease that is characterized by the presence of an abnormal protein called monoclonal protein in the blood.

Wikipedia : 74 Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia in which plasma... more...

Related Diseases for Monoclonal Gammopathy of Uncertain Significance

Diseases related to Monoclonal Gammopathy of Uncertain Significance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 532)
# Related Disease Score Top Affiliating Genes
1 waldenstroem's macroglobulinemia 31.9 SDC1 MYOM2 MAG IGHV4-38-2 CD40LG CD38
2 idiopathic neutropenia 31.3 TNF IL6 CD40LG
3 neuritis 31.3 TNF MAG IL6
4 polyneuropathy 31.2 TNF MAG IL6 CD40LG B2M
5 agammaglobulinemia 31.2 TNF IL6 CD40LG CD19
6 tetanus 31.2 TNF LTA IL6 CD40LG
7 pyoderma 31.2 TNF MYOM2 CD40LG
8 cytomegalovirus infection 31.2 TNF IL6 B2M
9 macroglobulinemia 31.1 SDC1 IL6 CD40LG
10 rubella 31.0 TNF IL6 CD40LG
11 cryoglobulinemia 31.0 TNF IL6 CD40LG
12 exanthem 30.9 TNF IL6 CD40LG
13 pericarditis 30.9 TNF IL6 CD40LG
14 fasciitis 30.9 TNF MYOM2 LTA IL6
15 spondylitis 30.9 TNF LTA IL6
16 plasma cell leukemia 30.9 SDC1 NCAM1 MIR19A MAF IL6 FGFR3
17 cellulitis 30.9 TNF IL6 CD40LG
18 purpura 30.9 TNF IL6 CD40LG
19 arthropathy 30.9 TNF LTA IL6 B2M
20 anemia, autoimmune hemolytic 30.9 IGHV4-38-2 CD40LG CD19
21 bacterial pneumonia 30.8 TNF IL6 CD40LG
22 mumps 30.8 TNF IL6 CD40LG
23 bone inflammation disease 30.8 TNF MIR126 IL6 CD40LG
24 connective tissue disease 30.8 TNF MIR126 IL6 CFHR2 CD40LG
25 spondyloarthropathy 1 30.8 TNF CFHR2 CD40LG B2M
26 toxic shock syndrome 30.8 TNF MYOM2 LTA IL6 CD40LG
27 gamma heavy chain disease 30.7 SDC1 IGHV4-38-2 CD40LG
28 plasmacytoma 30.7 NCAM1 IL6 CD38 B2M
29 poems syndrome 30.7 TNF MYOM2 IL6
30 amyloidosis 30.7 TNF MYOM2 IL6 CD40LG B2M
31 skin disease 30.7 TNF MIR126 IL6 FGFR3 CD40LG B2M
32 respiratory failure 30.7 TNF SDC1 LTA IL6 CD40LG
33 heavy chain disease 30.7 MYOM2 CFHR2 CD40LG
34 solitary osseous plasmacytoma 30.6 SDC1 NCAM1 MYOM2 CD38 B2M
35 lymphoma, mucosa-associated lymphoid type 30.6 SDC1 IGHV4-38-2 CD40LG CD19 B2M
36 mantle cell lymphoma 30.6 TNF IL6 CD40LG CD19 B2M
37 post-transplant lymphoproliferative disease 30.6 TNF LTA IL6 B2M
38 common variable immunodeficiency 30.6 TNF IL6 CD40LG CD38 CD19
39 demyelinating disease 30.6 TNF MIR126 MAG IL6 CD40LG
40 peripheral nervous system disease 30.6 TNF MYOM2 MIR126 MAG IL6 CD40LG
41 psoriatic arthritis 30.6 TNF LTA IL6 CD40LG
42 chronic polyneuropathy 30.5 MAG CD40LG
43 bone disease 30.5 TNF SDC1 LTA IL6 FGFR3 B2M
44 chickenpox 30.5 TNF IL6 CD40LG CD19
45 extramedullary plasmacytoma 30.5 SDC1 NCAM1 MYOM2 IL6 CD38 B2M
46 urticaria 30.5 TNF IL6 CD40LG
47 arteries, anomalies of 30.4 TNF MIR126 IL6 CFHR2
48 lipoprotein quantitative trait locus 30.4 TNF MIR126 IL6 CD40LG
49 immune deficiency disease 30.4 TNF LTA IL6 CFHR2 CD40LG CD38
50 pancytopenia 30.4 NCAM1 IL6 CD40LG CD19

Graphical network of the top 20 diseases related to Monoclonal Gammopathy of Uncertain Significance:



Diseases related to Monoclonal Gammopathy of Uncertain Significance

Symptoms & Phenotypes for Monoclonal Gammopathy of Uncertain Significance

MGI Mouse Phenotypes related to Monoclonal Gammopathy of Uncertain Significance:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 B2M CD19 CD38 CD40LG FGFR3 IL6
2 hematopoietic system MP:0005397 10.06 B2M CD19 CD38 CD40LG FGFR3 IL6
3 endocrine/exocrine gland MP:0005379 10.02 B2M CD38 CD40LG IL6 LTA MAFB
4 immune system MP:0005387 9.97 B2M CD19 CD38 CD40LG FGFR3 IL6
5 mortality/aging MP:0010768 9.77 B2M CD19 CD40LG FGFR3 IL6 LTA
6 nervous system MP:0003631 9.4 B2M CD19 CD40LG FGFR3 IL6 LTA

Drugs & Therapeutics for Monoclonal Gammopathy of Uncertain Significance

Drugs for Monoclonal Gammopathy of Uncertain Significance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 213)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Liraglutide Approved Phase 4 204656-20-2 44147092
2
Glucagon Approved Phase 4 16941-32-5
3 Immunoglobulins Phase 4
4 Antibodies Phase 4
5 Hormones Phase 4
6 Hormone Antagonists Phase 4
7 Hypoglycemic Agents Phase 4
8 Glucagon-Like Peptide 1 Phase 4
9 Incretins Phase 4
10
rituximab Approved Phase 3 174722-31-7 10201696
11
Ondansetron Approved Phase 3 99614-02-5 4595
12
Dalteparin Approved Phase 3 9005-49-6
13
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
14
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
15
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
16
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
19
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
20
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
22
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
23
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
24 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
25 Analgesics Phase 3
26 Antirheumatic Agents Phase 3
27 Antineoplastic Agents, Immunological Phase 3
28 Anticoagulants Phase 3
29 Anti-Bacterial Agents Phase 3
30 Gastrointestinal Agents Phase 3
31 Anti-Infective Agents Phase 3
32 Antiemetics Phase 3
33 Liver Extracts Phase 3
34 Anti-Anxiety Agents Phase 3
35 Psychotropic Drugs Phase 3
36 Neurotransmitter Agents Phase 3
37 Dermatologic Agents Phase 3
38 Antipsychotic Agents Phase 3
39 Fibrinolytic Agents Phase 3
40 Heparin, Low-Molecular-Weight Phase 3
41 Excitatory Amino Acid Antagonists Phase 3
42 Narcotics Phase 3
43 Analgesics, Opioid Phase 3
44 Hematinics Phase 3
45 Epoetin alfa Phase 3 113427-24-0
46 Anesthetics Phase 3
47 Anesthetics, General Phase 3
48 Anesthetics, Intravenous Phase 3
49 Cola Phase 3
50 Antifungal Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA) Not yet recruiting NCT02920190 Phase 4 Liraglutide
2 Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3 Rituximab
3 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
4 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
5 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
6 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
7 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
8 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
9 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
10 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
11 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
12 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
13 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2 beta alethine
15 Biologic and Clinical Role of COX-2 Inhibitor (Celecoxib)in the Management of MGUS and Smoldering Myeloma Completed NCT00099047 Phase 2 celecoxib;placebo
16 A Pilot Study of Novel Imaging Modalities in Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), and Multiple Myeloma (MM) Completed NCT01237054 Phase 2 18-NaF PET;18-FDG PET/CT
17 A Phase II Clinical Trial of Dehydroepiandrosterone and Biaxin in Monoclonal Gammopathy of Undetermined and Borderline Significance Completed NCT00006219 Phase 2 clarithromycin;prasterone
18 A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
19 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
20 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
21 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
22 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
23 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
24 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
25 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
26 A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
27 Safety, Tolerability, and Efficacy of Rituximab in Patients With Anti-Glycoconjugate Antibody-Mediated Demyelinating Neuropathy: A Double-Blind Placebo-Controlled Randomized Trial Completed NCT00050245 Phase 2 Rituximab
28 An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma Completed NCT01063907 Phase 1, Phase 2 KW-2478;Bortezomib
29 Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias Completed NCT02041325 Phase 2 Lenalidomide;Placebo
30 A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma Active, not recruiting NCT03236428 Phase 2 Daratumumab
31 Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In Not yet recruiting NCT04439006 Phase 2 Ibrutinib
32 Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies Terminated NCT00899353 Phase 2
33 A Phase II Trial of Lenalidomide as a Treatment for Neuropathy Associated With Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS) Terminated NCT00665652 Phase 2 Lenalidomide
34 A Phase II Trial of Rituximab for Peripheral Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS) Terminated NCT00588822 Phase 2
35 A Phase II Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma Terminated NCT01302366 Phase 2 TBL12
36 A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma Terminated NCT01096810 Phase 2 TBL 12
37 The Clinical and Biologic Evaluation of Polyphenon E, an Extract of Green Tea Containing EGCG, in Plasma Cell Dyscrasias - Pilot Study Terminated NCT00942422 Phase 2
38 Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma Terminated NCT01062230 Phase 2 Bortezomib (Velcade)
39 Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients Terminated NCT00983346 Phase 2 Bortezomib
40 Novel Imaging Modalities to Characterize Angiogenesis in the Bone Marrow Microenvironment in Multiple Myeloma (MM) and Its Precursor Disease Withdrawn NCT01571726 Phase 2 Fluciclatide
41 Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells Unknown status NCT00004036 Phase 1 amifostine trihydrate;carboplatin;cyclophosphamide
42 A Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) Effects on the QT Interval in Subjects With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Completed NCT01219010 Phase 1
43 A Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Patients With Advanced Solid Tumors and B-cell Lymphoproliferative Disorders Completed NCT00006362 Phase 1 bortezomib
44 A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00025415 Phase 1 imatinib mesylate
45 A Phase I Study of the Biologic and Clinical Effects of 5-AZA-2'Deoxycytidine (DAC) in Patients With Advanced Malignancies Completed NCT00002980 Phase 1 decitabine
46 Phase I Study of T Cell Depleted (TCD) Partially Matched Related Donor (PMRD) Hematopoietic Stem Cell Transplantation for High Risk Hematologic Diseases Using Intense Pre and Post Transplant Immunosuppression and Megadose CD34 "Veto" Cells Completed NCT00004904 Phase 1 cladribine;cyclophosphamide;etoposide;methylprednisolone;tacrolimus
47 A Phase I Trial of EMD 121974 in Patients With Advanced or Metastatic Cancer Completed NCT00004258 Phase 1 cilengitide
48 Phase I Trial of Interleukin-12 Followed by Interferon-Alpha Completed NCT00003451 Phase 1
49 A Phase I Study of Low Dose Continuous Infusion Topotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Malignancies Completed NCT00003331 Phase 1 fluorouracil;leucovorin calcium;topotecan hydrochloride
50 A Phase IA Trial of Combined Murine IgG Monoclonal Anti-Transferrin Receptor Antibodies E2.3 and A27.15 in Cancer Patients Completed NCT00003082 Phase 1

Search NIH Clinical Center for Monoclonal Gammopathy of Uncertain Significance

Genetic Tests for Monoclonal Gammopathy of Uncertain Significance

Anatomical Context for Monoclonal Gammopathy of Uncertain Significance

MalaCards organs/tissues related to Monoclonal Gammopathy of Uncertain Significance:

40
Bone, Bone Marrow, B Cells, T Cells, Testes, Kidney, Endothelial

Publications for Monoclonal Gammopathy of Uncertain Significance

Articles related to Monoclonal Gammopathy of Uncertain Significance:

(show top 50) (show all 1871)
# Title Authors PMID Year
1
Risk of mature B-cell neoplasms and precursor conditions after joint replacement: A report from the Haematological Malignancy Research Network. 61
31675431 2020
2
Bilateral Chondroid Metaplasia of Conjunctiva Associated With Monoclonal Gammopathy of Undetermined Significance. 61
32243417 2020
3
Acquired dysfibrinogenemia: monoclonal λ-type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formation. 61
32253663 2020
4
Nodular pulmonary deposition disease in a patient with the acquired immunodeficiency syndrome: a case report. 61
32498712 2020
5
[MPO-ANCA-associated hypertrophic pachymeningitis with monoclonal gammopathy of undetermined significance: a case report]. 61
32536662 2020
6
Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. 61
32569378 2020
7
Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. 61
32039495 2020
8
Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance. 61
32478420 2020
9
Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All. 61
32545521 2020
10
Insulin autoimmune syndrome. 61
32554828 2020
11
The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions. 61
31999849 2020
12
Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience. 61
32567936 2020
13
Crystalglobulinemia manifested as acute renal failure and thrombotic vasculopathy. 61
32533290 2020
14
Pyoderma gangrenosum in hematologic malignancies: A systematic review. 61
31560977 2020
15
A case series of Monoclonal Gammopathy of Undetermined Significance and COVID-19. 61
32479664 2020
16
Monoclonal gammopathy of undetermined significance in medical hospital admissions - a new strategy for screening? 61
32072614 2020
17
Unusual Spherical Bodies in Bone Marrow of a Patient with Monoclonal Gammopathy of Undetermined Significance (MGUS). 61
32539317 2020
18
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. 61
32442065 2020
19
Crystalglobulin-associated nephropathy presenting as MGRS in a case of monoclonal B-cell lymphocytosis: a case report. 61
32423442 2020
20
Hematological Diseases and Osteoporosis. 61
32429497 2020
21
Circulating extracellular vesicle-associated CD163 and CD206 in multiple myeloma. 61
31855290 2020
22
Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. 61
32144026 2020
23
Unusual manifestation of monoclonal gammopathy of undetermined significance: a false serum creatinine elevation. 61
31838713 2020
24
Massive Hepatomegaly Secondary to Amyloidosis with Normal Liver Chemistries. 61
32518538 2020
25
Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. 61
32370855 2020
26
Spinal Cord Impairment in Anti-Mag Neuropathy: Evidence from Somatosensory Evoked Potentials. 61
32397154 2020
27
Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. 61
32456143 2020
28
Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules. 61
32453840 2020
29
The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? 61
32376870 2020
30
Scleromyxedema with multiple systemic involvement: Successful treatment with intravenous immunoglobulin. 61
32250023 2020
31
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression. 61
32354870 2020
32
Recent Advances in the Management of Smoldering Multiple Myeloma. 61
32284772 2020
33
Coexistence of Serum Monoclonal Gammopathy of Uncertain Significance and Hodgkin Lymphoma. 61
32425396 2020
34
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma. 61
32290052 2020
35
Epidemiological and immunochemical parameters of monoclonal plasma cell dyscrasias of 2121 cases in Algeria. 61
31761679 2020
36
Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects. 61
32222885 2020
37
Autoimmune retinopathy associated with monoclonal gammopathy of undetermined significance: a case report. 61
32299429 2020
38
Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance. 61
32285757 2020
39
Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance. 61
32360588 2020
40
Prevalence and prognostic value of monoclonal gammopathy in heart failure patients with preserved ejection fraction: A prospective study. 61
32329041 2020
41
Ex vivo/in vitro protective effect of myricetin bulk and nano-forms on PhIP-induced DNA damage in lymphocytes from healthy individuals and pre-cancerous MGUS patients. 61
32342131 2020
42
ROS-induced oxidative damage in lymphocytes ex vivo/in vitro from healthy individuals and MGUS patients: protection by myricetin bulk and nanoforms. 61
32107588 2020
43
A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. 61
31848687 2020
44
Synchronous multiple myeloma and Gaucher disease. 61
31622574 2020
45
Prevalence of monoclonal gammopathy of undetermined significance in a large population with annual medical check-ups in China. 61
32152278 2020
46
[Monoclonal gammopathy of undetermined significance]. 61
32138824 2020
47
Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. 61
32340914 2020
48
Maculopathy in Patients with Monoclonal Gammopathy of Undetermined Significance. 61
31753810 2020
49
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. 61
32085480 2020
50
Dissecting racial disparities in multiple myeloma. 61
32066732 2020

Variations for Monoclonal Gammopathy of Uncertain Significance

Copy number variations for Monoclonal Gammopathy of Uncertain Significance from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13350 1 1 125000000 Gain Monoclonal gammopathy of undetermined significance
2 16482 1 125000000 249250621 Gain Monoclonal gammopathy of undetermined significance
3 55476 11 53700000 135006516 Gain Monoclonal gammopathy of undetermined significance
4 76533 13 32200000 40100000 Deletion NBEA Monoclonal gammopathy of undetermined significance
5 82835 14 17600000 107349540 Loss Monoclonal gammopathy of undetermined significance
6 89754 15 19000000 102531392 Gain Monoclonal gammopathy of undetermined significance
7 124088 19 1 26500000 Gain Monoclonal gammopathy of undetermined significance
8 166137 3 1 91000000 Gain Monoclonal gammopathy of undetermined significance
9 214491 6 61000000 171115067 Loss Monoclonal gammopathy of undetermined significance
10 253951 9 49000000 141213431 Gain Monoclonal gammopathy of undetermined significance

Expression for Monoclonal Gammopathy of Uncertain Significance

Search GEO for disease gene expression data for Monoclonal Gammopathy of Uncertain Significance.

Pathways for Monoclonal Gammopathy of Uncertain Significance

Pathways related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.18 TNF NCAM1 LTA IL6 FGFR3 CD40LG
2
Show member pathways
12.7 TNF LTA IL6 CD40LG B2M
3
Show member pathways
12.45 TNF LTA IL6 FGFR3 CD40LG
4 12.25 TNF NCAM1 CD40LG CD38 CD19 B2M
5 12.12 TNF LTA IL6 B2M
6 11.88 SDC1 NCAM1 MAG CD40LG
7 11.66 TNF IL6 CD38 CD19
8
Show member pathways
11.64 TNF LTA CD40LG
9 11.62 TNF NCAM1 LTA
10 11.6 SDC1 NCAM1 IL6 CD19
11
Show member pathways
11.57 TNF MAF CD40LG
12
Show member pathways
11.43 TNF IL6 CD40LG
13 11.22 TNF NCAM1 IL6 CD38 CD19
14 11.16 TNF SDC1 IL6 CD40LG
15 11.16 TNF SDC1 NCAM1 IL6 CD38 CD19
16 10.45 TNF MIR126

GO Terms for Monoclonal Gammopathy of Uncertain Significance

Cellular components related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 TNF SDC1 NCAM1 LTA IL6 FGFR3
2 cell surface GO:0009986 9.5 TNF SDC1 NCAM1 FGFR3 CD40LG CD38
3 external side of plasma membrane GO:0009897 9.17 TNF SDC1 NCAM1 IGHV4-38-2 CD40LG CD19

Biological processes related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.92 TNF LTA IL6 CD40LG B2M
2 positive regulation of protein kinase B signaling GO:0051897 9.71 TNF MIR126 FGFR3 CD19
3 negative regulation of neuron projection development GO:0010977 9.65 MAG CD38 B2M
4 response to glucocorticoid GO:0051384 9.63 TNF SDC1 IL6
5 humoral immune response GO:0006959 9.61 TNF LTA IL6
6 positive regulation of neuroinflammatory response GO:0150078 9.54 TNF IL6
7 negative regulation of lipid storage GO:0010888 9.51 TNF IL6
8 cellular response to nicotine GO:0071316 9.49 TNF B2M
9 negative regulation of neurogenesis GO:0050768 9.43 TNF IL6 B2M
10 regulation of immunoglobulin secretion GO:0051023 9.37 TNF CD40LG
11 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.32 TNF LTA
12 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.16 TNF LTA
13 positive regulation of glial cell proliferation GO:0060252 9.13 TNF LTA IL6
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.92 TNF MIR19A IL6 FGFR3

Molecular functions related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 TNF SDC1 MAFB FGFR3 CFHR2 CD38
2 cytokine activity GO:0005125 9.26 TNF LTA IL6 CD40LG
3 tumor necrosis factor receptor binding GO:0005164 8.8 TNF LTA CD40LG

Sources for Monoclonal Gammopathy of Uncertain Significance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....